Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.
Intern Med
; 60(4): 639-643, 2021 Feb 15.
Article
in English
| MEDLINE | ID: covidwho-1082267
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Sjogren's Syndrome
/
Off-Label Use
/
Antibodies, Monoclonal, Humanized
/
COVID-19
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Male
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Internalmedicine.6010-20
Similar
MEDLINE
...
LILACS
LIS